menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

A Treatment for Schizophrenia in Adults

A Treatment for Schizophrenia in Adults
RestartResume
Please see Important Safety Information, including Boxed Warning.
Host Dr. Matt Birnholz and guest expert, Dr. Roger McIntyre...
  • Overview

    Please see Important Safety Information, including Boxed Warning.

    Host Dr. Matt Birnholz and guest expert, Dr. Roger McIntyre will discuss the clinical profile of SAPHRIS® (asenapine) sublingual tablets for the acute and maintenance treatment of schizophrenia in adults. They will also review the safety data for SAPHRIS from the adult schizophrenia clinical trials and Important Safety Information, including Boxed Warning, for SAPHRIS. Dr. McIntyre is Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network. He has published extensively on these and related topics and was one of the principal investigators in the Saphris bipolar I disorder trials. Dr. Roger McIntyre is a paid consultant for Actavis.
    This program is intended for U.S. healthcare professionals

    IMPORTANT SAFETY INFORMATION, including BOXED WARNING

    WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

    Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. SAPHRIS is not approved for treatment of patients with dementia-related psychosis.

    Contraindications:SAPHRIS is contraindicated in patients with severe hepatic impairment (Child-Pugh C) or known hypersensitivity to SAPHRIS or its formulation components. Reactions have included anaphylaxis and angioedema.

    Cerebrovascular Adverse Events, Including Stroke:In clinical trials with antipsychotic drugs, elderly subjects with dementia had a higher incidence of cerebrovascular adverse reactions, including fatalities vs placebo. SAPHRIS is not approved for the treatment of patients with dementia-related psychosis.

    Neuroleptic Malignant Syndrome (NMS): NMS, a potentially fatal symptom complex, has been reported with antipsychotics, including SAPHRIS. NMS may cause hyperpyrexia, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia. Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. Management includes immediate discontinuation of antipsychotics and other drugs not essential to concurrent therapy, intensive symptomatic treatment and monitoring, and treatment of any concomitant serious medical problems.

    Tardive Dyskinesia (TD): Risk of developing TD (a syndrome of potentially irreversible, involuntary dyskinetic movements) and the likelihood it will become irreversible may increase as the duration of treatment and total cumulative dose of antipsychotic drugs given to the patient increase. The syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. Prescribe SAPHRIS in a manner most likely to minimize TD. If signs and symptoms of TD appear, drug discontinuation should be considered.

    Metabolic Changes: Atypical antipsychotics have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk:

    • Hyperglycemia and Diabetes Mellitus: Hyperglycemia, in some cases associated with ketoacidosis, hyperosmolar coma, or death, has been reported in patients treated with atypical antipsychotics. Patients with risk factors for diabetes mellitus starting treatment with antipsychotics should undergo fasting blood glucose testing at the beginning of and during treatment. Monitor any patient treated with antipsychotics for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop these symptoms during treatment should undergo fasting blood glucose testing. In some cases, hyperglycemia resolved when the antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the antipsychotic drug.
    • Dyslipidemia: Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.
    • Weight Gain: Increases in weight have been observed with SAPHRIS. Monitor weight regularly in patients on SAPHRIS.

    Hypersensitivity Reactions: Hypersensitivity reactions, including anaphylaxis, angioedema, hypotension, tachycardia, swollen tongue, dyspnea, wheezing, and rash, have been observed in patients treated with SAPHRIS. In several cases, these reactions occurred after the first dose.

    Orthostatic Hypotension, Syncope, and Other Hemodynamic Effects: SAPHRIS may induce orthostatic hypotension and syncope. Use SAPHRIS with caution in patients with cardiovascular/cerebrovascular diseases, conditions which predispose to hypotension, and in the elderly. Use SAPHRIS cautiously with other drugs that can induce hypotension, bradycardia, or respiratory or central nervous system depression. Monitor orthostatic vital signs, and consider a dose reduction if hypotension occurs.

    Leukopenia, Neutropenia, and Agranulocytosis: Leukopenia/neutropenia have been reported with antipsychotics, including SAPHRIS. Agranulocytosis (including fatal cases) has been reported with other antipsychotics. Monitor complete blood count in patients with pre-existing low white blood cell count (WBC)/absolute neutrophil count or history of drug-induced leukopenia/neutropenia. Discontinue SAPHRIS at the first sign of a clinically significant decline in WBC and in severely neutropenic patients.

    QT Prolongation: In an adult QT study, SAPHRIS was associated with increases in the QTc interval from 2 to 5 msec vs placebo. No SAPHRIS patients had QTc increases of ≥60 msec or a QTc of ≥500 msec. Avoid SAPHRIS in combination with other drugs known to prolong QTc interval, in patients with congenital prolongation of QT interval or a history of cardiac arrhythmias, and in circumstances that may increase occurrence of torsades de pointes and/or sudden death in association with the use of drugs that prolong QTc interval.

    Hyperprolactinemia: Like other drugs that antagonize dopamine D2 receptors, SAPHRIS can elevate prolactin levels and the elevation can persist during chronic administration. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds.

    Seizures: Use SAPHRIS with caution in patients with history of seizures or with conditions that lower the seizure threshold.

    Potential for Cognitive and Motor Impairment: Somnolence was reported with SAPHRIS. Caution patients about performing activities requiring mental alertness (eg, operating hazardous machinery or a motor vehicle).

    Body Temperature Regulation: Appropriate care is advised when using SAPHRIS in patients who will experience conditions that increase body temperature, eg, exercising strenuously, extreme heat, concomitant anticholinergics, or dehydration.

    Suicide: The possibility of suicide attempt is inherent in psychotic illnesses and bipolar disorder. Close supervision of high-risk patients should accompany drug therapy. Prescriptions should be written for the smallest quantity of tablets to reduce risk of overdose.

    Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotics. Aspiration pneumonia is a common cause of morbidity/mortality in elderly patients, in particular those with advanced Alzheimer’s dementia. SAPHRIS should not be used in patients at risk for aspiration pneumonia.

    Drug Interactions: Monitor blood pressure and adjust antihypertensive drugs when taken with SAPHRIS. Based on clinical response, SAPHRIS dose reduction may be necessary when used with strong CYP1A2 inhibitors (fluvoxamine). Reduce paroxetine (CYP2D6 substrate and inhibitor) dose by half when taken with SAPHRIS.

    Pregnancy: Advise patients to notify their healthcare provider of a known or suspected pregnancy. SAPHRIS may cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure. Based on animal data, SAPHRIS may cause fetal harm. The National Pregnancy Registry for Atypical Antipsychotics monitors pregnancy outcomes in women exposed to antipsychotics, including SAPHRIS, during pregnancy. For information, contact 1-866-961-2388 or http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/.

    Adverse Reactions: In adult clinical trials with SAPHRIS (5 and 10 mg BID) vs placebo, commonly observed adverse reactions (≥5% and at least twice the rate of placebo) were:

    • Schizophrenia: akathisia (6% vs 3%), oral hypoesthesia (5% vs 1%), and somnolence (13% vs 7%)

    Postmarketing Experience: Application site reactions, primarily sublingual, have been reported (eg, oral ulcers, blisters, peeling/sloughing, and inflammation). Choking has been reported, sometimes associated with oropharyngeal muscular dysfunction or hypoesthesia.

    Please click here for full Prescribing Information, including Boxed Warning.

    Sponsored by

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.